Triple Elimination of Mother-to-Child Transmission of HIV

By Crystal Lubbe

December 3, 2024

The World Health Organization (WHO) Regional Office for Africa has initiated a pivotal effort for triple elimination of HIV in Africa titled “New step in African region’s efforts to eliminate mother-to-child transmission of HIV, syphilis and hepatitis B.” This article outlines key initiatives aimed at combating these infections. Notably, a central focus is the establishment of the Regional Validation Committee, which is essential for overseeing the national validation reports concerning the elimination of mother-to-child transmission (MTCT) of HIV, syphilis, and hepatitis B.

Launch of the Regional Validation Committee

The WHO Regional Office for Africa has established a Regional Validation Committee to verify the national validation reports for the elimination of mother-to-child transmission of HIV, syphilis, and hepatitis B. This committee plays a critical role in ensuring the quality and validity of the elimination reports and certifying countries that meet their goals.

Validation Process

The validation process is transparent and follows standardised criteria and tools. It includes a rigorous assessment at national, regional, and global levels, focusing on significant impact indicators and foundational requirements: data quality, programs, laboratory quality, and community engagement, alongside human rights and gender equality.

Membership and Inaugural Meeting

The Regional Validation Committee comprises experts from countries including Botswana, Cameroon, Ethiopia, Ghana, Kenya, South Africa, Uganda, the United States, and Zimbabwe. The inaugural meeting took place in Brazzaville on November 25-26, 2024.

Commitment and Progress

The committee’s formation highlights the commitment of countries and WHO to help achieve triple infection elimination. The African region has made significant progress against HIV, with over 21.3 million on antiretroviral treatment and 90% of pregnant women in Eastern and Southern Africa receiving therapy to protect infants. Nevertheless, progress remains slow in West and Central Africa.

Role of the Committee

The committee is tasked with reviewing national reports, identifying gaps, and assisting countries in adhering to stringent validation standards. Its aim is to validate and catalyse the development of stronger, more resilient health systems.

Framework and Certification

Guided by WHO’s Framework for Triple Elimination, the committee offers high-burden countries a clear progress roadmap. Notable successes include Botswana achieving silver-tier status for HIV elimination and Namibia’s advancements in hepatitis B and HIV elimination.

Broader Context

The triple elimination agenda fits into broader efforts to reduce disease burden in Africa. Moreover, and importantly, this aligns with global strategies, such as the Global Strategy for Women, Children, and Adolescents’ Health (2016–2030).

In summary, it emphasises the need for the WHO and African nations to eliminate MTCT of HIV. Consequently, it highlights the Regional Validation Committee’s role in validating progress and strengthening health systems across the continent. This endeavor reflects the determination to achieve tangible results in the fight against these infections.

Reference url

Recent Posts

preventive health costs
       

Prevention Valuation: Fund Health, Not Just Savings

💡 Is prevention really saving us money in healthcare?

In their thought-provoking article, “Can Prevention Save Money?”, Baicker and Chandra challenge the prevailing notion that preventive health measures always reduce costs. They argue that while prevention can enhance health outcomes, it often leads to increased spending upfront, and the key lies in evaluating these programs based on their cost-effectiveness instead of expecting them to save money outright.

Curious about the real financial implications of preventive care? Dive into the full analysis to uncover the nuances!

#SyenzaNews #HealthEconomics #costeffectiveness #healthcarepolicy

FDA AI Drug Approval
          

FDA AI Drug Approval

🚀 Are we on the brink of a new era in drug approval?

The FDA’s new AI initiative is set to reshape how we evaluate new therapies by dramatically speeding up the review process. With generative AI tools already cutting down review times from days to mere minutes, this breakthrough will not only enhance efficiency but also enable scientists to focus on more impactful work.

Curious about the implications for market access, patient outcomes, and health economics? Dive into the full article to explore how the future of pharmaceutical approvals is being transformed!

#SyenzaNews #regulatoryaffairs #AIinHealthcare #innovation

HCV treatment advancements
      

HCV Treatment Advancements: Atea Pharmaceuticals KOL Panel

🌍 Are we on the brink of a new era in Hepatitis C treatment?

Atea Pharmaceuticals is hosting a virtual KOL panel on May 14, 2025, featuring top experts discussing the challenges faced by HCV patients and sharing insights from the promising results of their Phase 2 study on bemnifosbuvir and ruzasvir. This could be a game-changer in advancing HCV treatments through ongoing Phase 3 trials.

Don’t miss out on how these developments might reshape the future landscape for HCV patients! Click to read more about the panel and the innovative therapies in the pipeline.

#SyenzaNews #biotechnology #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.